Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages
- PMID: 25134819
- PMCID: PMC4287110
- DOI: 10.1089/AID.2014.0133
Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages
Abstract
In a prospective cross-sectional study we quantified HIV viral load within the alveolar macrophage in a cohort of healthy HIV-infected subjects who did not have medical comorbidities or smoke cigarettes to determine if alveolar macrophage proviral DNA was associated with alveolar macrophage phagocytic immune dysfunction. We enrolled 23 subjects who underwent bronchoscopy and bronchoalveolar lavage. Alveolar macrophages were isolated and HIV-1 RNA was quantified in the cells using the Abbott RealTime HIV-1 Assay. Proviral DNA was qualitatively measured using a modified version of the HIV-1 RNA assay. Phagocytosis measured by incubating alveolar macrophages with FITC-labeled Staphylococcus aureus and determining fluorescence with a Zeiss inverted microscope. Phagocytic index was calculated as (% positive cells × mean channel fluorescence)/100. Sixteen subjects had (+) proviral DNA and seven had (-) proviral DNA in their alveolar macrophages. Of all subjects 100% in both groups were on highly active antiretroviral therapy (HAART). The median plasma viral load was 0 in both groups. HIV-1-infected subjects with (+) proviral DNA in their alveolar macrophages had a significantly lower median alveolar macrophage phagocytic index compared to those with (-) proviral DNA in their alveolar macrophages [11.8 (IQR 4.8-39.0) vs. 64.9 (IQR 14.0-166.0), p = 0.05]. Alveolar macrophages harbor HIV even in otherwise healthy subjects with undetectable plasma viral loads, representing a potential reservoir for the virus. In addition, HIV viral replication within the macrophage may impair phagocytosis and other immune functions in the lung, leading to an increased risk for lung infection.
Figures
Similar articles
-
Dysregulation of Alveolar Macrophage PPARγ, NADPH Oxidases, and TGFβ1 in Otherwise Healthy HIV-Infected Individuals.AIDS Res Hum Retroviruses. 2017 Oct;33(10):1018-1026. doi: 10.1089/AID.2016.0030. Epub 2017 Apr 24. AIDS Res Hum Retroviruses. 2017. PMID: 28314381 Free PMC article.
-
Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.AIDS. 2001 Apr 13;15(6):665-73. doi: 10.1097/00002030-200104130-00001. AIDS. 2001. PMID: 11371680
-
HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.Clin Microbiol Infect. 2010 Jun;16(6):640-6. doi: 10.1111/j.1469-0691.2009.02826.x. Epub 2009 Sep 2. Clin Microbiol Infect. 2010. PMID: 19732081
-
Single-molecule techniques to quantify and genetically characterise persistent HIV.Retrovirology. 2018 Jan 9;15(1):3. doi: 10.1186/s12977-017-0386-x. Retrovirology. 2018. PMID: 29316955 Free PMC article. Review.
-
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.New Microbiol. 2006 Apr;29(2):81-8. New Microbiol. 2006. PMID: 16841548 Review.
Cited by
-
Peering into the HIV reservoir.Rev Med Virol. 2018 Jul;28(4):e1981. doi: 10.1002/rmv.1981. Epub 2018 May 9. Rev Med Virol. 2018. PMID: 29744964 Free PMC article. Review.
-
Inhibition of the lncRNA SAF drives activation of apoptotic effector caspases in HIV-1-infected human macrophages.Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7431-7438. doi: 10.1073/pnas.1818662116. Epub 2019 Mar 27. Proc Natl Acad Sci U S A. 2019. PMID: 30918127 Free PMC article.
-
The Landscape of IFN/ISG Signaling in HIV-1-Infected Macrophages and Its Possible Role in the HIV-1 Latency.Cells. 2021 Sep 9;10(9):2378. doi: 10.3390/cells10092378. Cells. 2021. PMID: 34572027 Free PMC article. Review.
-
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.Microorganisms. 2021 Jun 27;9(7):1389. doi: 10.3390/microorganisms9071389. Microorganisms. 2021. PMID: 34198973 Free PMC article. Review.
-
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Front Immunol. 2017 Nov 28;8:1655. doi: 10.3389/fimmu.2017.01655. eCollection 2017. Front Immunol. 2017. PMID: 29234320 Free PMC article. Review.
References
-
- El-Sadr WM, Lundgren JD, Neaton JD, et al. : CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355(22):2283–2296 - PubMed
-
- Jordano Q, Falco V, Almirante B, et al. : Invasive pneumococcal disease in patients infected with HIV: Still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004;38(11):1623–1628 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
